News|Articles|November 21, 2026

Tenecteplase Bridging Therapy Associated With Lower Mortality Than Alteplase in Large Vessel Occlusion Stroke

Listen
0:00 / 0:00

Key Takeaways

  • TriNetX retrospective cohorts (n=2322 per arm after matching) showed 90-day mortality of 12.4% with tenecteplase versus 16.1% with alteplase (RR 0.78; P<.001).
  • New speech and movement deficits were less frequent with tenecteplase (13.6% vs 17.8%; 18.7% vs 27.2%), suggesting potential functional benefit beyond survival.
SHOW MORE

In a real-world cohort, tenecteplase before thrombectomy was associated with lower mortality and fewer new speech and movement deficits than alteplase, without an increase in symptomatic intracranial hemorrhage.

New data suggest that tenecteplase (TNK) used as bridging thrombolysis before mechanical thrombectomy for large vessel occlusion (LVO) stroke was associated with lower 90-day mortality and fewer new speech and movement deficits than alteplase, without a significant increase in symptomatic intracranial hemorrhage (sICH) or cognitive deficits in a propensity-matched analysis.1

The study was presented at the 2026 Society of Vascular and Interventional Neurology (SVIN) Annual Meeting, held November 17 to 20, in Las Vegas, Nevada, by senior author Lama Al-Khoury, MD, a neurologist at University of California, Riverside School of Medicine, and colleagues. The 2026 American Heart Association/American Stroke Association guideline endorses either TNK or alteplase within the 4.5-hour treatment window.2 The investigators noted that results from the EXTEND-IA TNK trial warranted further real-world evaluation of the 2 agents’ comparative safety and effectiveness as bridging therapy before endovascular thrombectomy.1

Researchers conducted a retrospective cohort study using the TriNetX US Collaborative Network, which comprises 67 health care organizations, queried on April 30, 2026. The study included adults 18 years and older with acute ischemic stroke (ICD-10 code I63.x) who underwent mechanical thrombectomy on the same day as diagnosis. Patients who received TNK on the stroke date with no record of alteplase (n = 2350) were compared with those who received alteplase with no record of TNK (n = 4703). Patients with neurologic deficits or dementia coded at least 1 day before the stroke were excluded.

After 1:1 propensity score matching on demographics, comorbidities, tobacco and alcohol use, antithrombotic and statin use, and prior physical therapy or physical medicine and rehabilitation evaluation, each cohort included 2322 patients, with all standardized mean differences below 0.1. Outcomes assessed from days 1 through 90 included all-cause mortality, sICH, and new speech, movement, and cognitive deficits.

Mortality and Functional Deficit Findings

Ninety-day mortality occurred in 12.4% of the TNK group compared with 16.1% of the alteplase group (risk ratio [RR], 0.78; 95% CI, 0.67-0.89; P <.001), an absolute difference of 3.7 percentage points. New speech deficits were reported in 13.6% vs 17.8% of patients, respectively (RR, 0.77; 95% CI, 0.59-0.99; P = .041), and new movement deficits in 18.7% vs 27.2% (RR, 0.69; 95% CI, 0.55-0.86; P = .001).

READ MORE: Infarct Size Alone Doesn't Predict Thrombectomy Outcomes, Registry Shows

Symptomatic ICH rates were similar between the TNK and alteplase groups (5.9% vs 6.5%; RR, 0.91; 95% CI, 0.70-1.18; P = .467). New cognitive deficits were numerically more frequent with TNK (6.0% vs 5.1%), although the difference was not statistically significant (RR, 1.19; 95% CI, 0.94-1.52; P = .157).

Building on Trial Evidence for Tenecteplase

TNK is administered as a single intravenous bolus, whereas alteplase requires a bolus followed by a 60-minute infusion.1 In the EXTEND-IA TNK trial of 202 patients with LVO, TNK resulted in a higher incidence of reperfusion before thrombectomy than alteplase (22% vs 10%) and better 90-day functional outcomes.3 A prespecified secondary analysis of the ACT trial, which included 520 patients with LVO, found similar rates of excellent functional outcome, sICH, mortality, and reperfusion with TNK and alteplase.4 The authors noted their real-world findings are consistent with current guidelines supporting TNK as an alternative to alteplase before thrombectomy.1

The investigators acknowledged several limitations. The retrospective, observational design leaves potential for residual confounding from unmeasured variables not captured in coded data, despite propensity score matching. Reliance on ICD-10, CPT, and RxNorm codes limited verification of thrombolytic dosing and clinical outcomes. Exclusion of index-date events may have missed early hemorrhagic complications, and baseline deficit analyses were restricted to a subgroup. Comorbidities, outside-network care, and out-of-network mortality may also have been incompletely captured, and no adjustment was made for multiple comparisons.

Looking ahead, the investigators recommended stratifying patients by National Institutes of Health Stroke Scale severity (minor, moderate, and severe) to determine whether the observed TNK associations differ by stroke burden. They added that further information on thrombolytic dosing, treatment timing, and modified Rankin Scale scores could better assess the effectiveness of either thrombolytic in bridging therapy.

Click here for more of our SVIN 2026 coverage.

REFERENCES
1. Wijaya E, Alrawi Z, Poschl I, Al-Khoury L. Evaluating 90-day outcomes of tenecteplase versus alteplase in bridging therapy for large vessel occlusion stroke. Presented at: 2026 Society of Vascular and Interventional Neurology Annual Meeting; November 17-20, 2026; Las Vegas, NV.
2. Prabhakaran S, Gonzalez NR, Zachrison KS, et al. 2026 Guideline for the early management of patients with acute ischemic stroke: a guideline from the American Heart Association/American Stroke Association. Stroke. 2026;57(8):e316-e436. doi:10.1161/STR.0000000000000513
3. Campbell BCV, Mitchell PJ, Churilov L, et al; EXTEND-IA TNK Investigators. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med. 2018;378(17):1573-1582. doi:10.1056/NEJMoa1716405
5. Bala F, Singh N, Buck B, et al. Safety and efficacy of tenecteplase compared with alteplase in patients with large vessel occlusion stroke: a prespecified secondary analysis of the ACT randomized clinical trial. JAMA Neurol. 2023;80(8):824-832. doi:10.1001/jamaneurol.2023.2094

Related to this article